$SMMT News

Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet

Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It

Summit Therapeutics Withdraws Previously Announced Proposed $500M Underwritten Public Offering Of Shares Due To Market Conditions

Summit Therapeutics Launches $500M Public Stock Offering To Fund Ivonescimab Development

Summit Therapeutics Files For Mixed Shelf Offering; Size Not Disclosed

Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress - Slideshow

Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress Transcript

Bernstein Initiates Coverage On Summit Therapeutics with Underperform Rating, Announces Price Target of $7.7

HC Wainwright & Co. Downgrades Summit Therapeutics to Neutral

Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary

HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $23

Piper Sandler Maintains Neutral on Summit Therapeutics, Lowers Price Target to $16

Summit Therapeutics Stock Dips After Q1 Financial Report

Summit Therapeutics: It Still Feels Like The Market Got Ahead Of Itself

Stifel Initiates Coverage On Summit Therapeutics with Buy Rating, Announces Price Target of $45

Jefferies Downgrades Summit Therapeutics to Hold, Lowers Price Target to $15

Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript

Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $30